While it has been shown that increased levels of plasma visfatin are associated with the development of CKD and podocyte damage, the precise mechanism by which this adipokine, visfatin, contributes to glomerular sclerosis or end-stage renal disease (ESRD) remains unclear. The gene discussed is NAMPT; the disease is glomerulosclerosis.